Efficacy and safety of tigecycline versus levofloxacin for community-acquired pneumonia

BMC Pulmonary Medicine

Volumn 9, Issue , 2009, Pages 44-

  Tanaseanu, Cristina ^a   Milutinovic, Slobodan ^b   Calistru, Petre I ^c   Strausz, Janos ^d   Zolubas, Marius ^e   Chernyak, Valeriy ^f   Dartois, Nathalie ^g   Castaing, Nathalie ^g   Gandjini, Hassan ^g   Cooper, C Angel ^h  

^a St Pantelimon Clinical Emergency Hospital   (Romania)

^b Sveti Duh General Hospital   (Croatia)

^c VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^d Pulmonology Hospital   (Hungary)

^e Klaipeda Regional Hospital   (Lithuania)

^f Cherkassy Regional Cardiology Center   (Ukraine)

^g Clinical Research and Development   (France)

^h PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; TIGECYCLINE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HOSPITAL PATIENT; HUMAN; HYPOKALEMIA; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PHASE 3 CLINICAL TRIAL; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE; THROMBOCYTOPENIA; THROMBOCYTOSIS; VOMITING;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MINOCYCLINE; NAUSEA; OFLOXACIN; PNEUMONIA, BACTERIAL; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 70449359990     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-9-44     Document Type: Article

References (25)

1. Aleva RM, Boersma WG: Guideline 'Diagnosis and treatment of community-acquired pneumonia' from the Dutch Thoracic Society. Ned Tijdschr Geneeskd 2005, 149:2501-2507.
2. Woodhead M: Community-acquired pneumonia in Europe: causative pathogens and resistance patterns. Eur Respir J Suppl 2002, 36:20s-27s.
3. Viegi G, Pistelli R, Cazzola M, Falcone F, Cerveri I, Rossi A, Ugo Di Maria G: Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy. Respir Med 2006, 100:46-55.
4. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN: Prognosis and outcomes of patients with community- acquired pneumonia. A meta-analysis. JAMA 1996, 275:134-141.
5. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ: Practice guidelines for the management of communityacquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000, 31:347-382.
6. Marrie TJ, Peeling RW, Fine MJ, Singer DE, Coley CM, Kapoor WN: Ambulatory patients with community-acquired pneumonia: the frequency of atypical agents and clinical course. Am J Med 1996, 101:508-515.
7. File TM Jr, Garau J, Blasi F, Chidiac C, Klugman K, Lode H, Lonks JR, Mandell L, Ramirez J, Yu V: Guidelines for empiric antimicrobial prescribing in community-acquired pneumonia. Chest 2004, 125:1888-1901.
8. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C: Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003, 37:405-1433.
9. Campbell GD, Dean N, File MJ, Gross PA, Martinez F, Marrie TJ, Plouffe JF, Ramirez J, Sarosi GA, Torres A, Wilson R, Yu VL: Guidelines for the management of adults with communityacquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001, 163:1730-1754.
10. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, Heijden G van der, Verheij TJ: Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005, 26:1138-1180.
11. Felmingham D: Comparative antimicrobial susceptibility of respiratory tract pathogens. Chemotherapy 2004, 50(Suppl 1):3-10.
12. Gordon KA, Biedenbach DJ, Jones RN: Comparison of Streptococcus pneumoniae and Haemophilus influenzae susceptibilities from community-acquired respiratory tract infections and hospitalized patients with pneumonia: five-year results for the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2003, 46:285-289.
13. Johnson DM, Stilwell MG, Fritsche TR, Jones RN: Emergence of multidrug-resistant Streptococcus pneumoniae: report from the SENTRY Antimicrobial Surveillance Program (1999-2003). Diagn Microbiol Infect Dis 2006, 56:69-74.
14. Whitney CG, Farley MM, Hadler J, Harrison LH, Lexau C, Reingold A, Lefkowitz L, Cieslak PR, Cetron M, Zell ER, Jorgensen JH, Schuchat A: Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States. N Engl J Med 2000, 343:1917-1924.
15. Hoban DJ, Biedenbach DJ, Mutnick AH, Jones RN: Pathogen of occurrence and susceptibility patterns associated with pneumonia in hospitalized patients in North America: results of the SENTRY Antimicrobial Surveillance Study (2000). Diagn Microbiol Infect Dis 2003, 45:279-285.
16. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN: A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997, 336:243-250.
17. Lim WS, Eerden MM van der, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-382.
18. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN: Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 2005, 52:187-193.
19. Ko KS, Song JH, Lee MY, Park S, Kwon KT, Heo ST, Ryu SY, Oh WS, Peck KR, Lee NY: Antimicrobial activity of tigecycline against recent isolates of respiratory pathogens from Asian countries. Diagn Microbiol Infect Dis 2006, 55:337-341.
20. Olson MW, Ruzin A, Feyfant E, Rush TS 3rd, O'Connell J, Bradford PA: Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother 2006, 50:2156-2166.
21. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E: The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005, 41(Suppl 5):S354-S367.
22. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E: The efficacy and safety of tigecycline in the treatment of skin and skinstructure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005, 41(Suppl 5):S341-S353.
23. Salkind AR, Cuddy PG, Foxworth JW: Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis. Ann Pharmacother 2002, 36:1938-1943.
24. Carrie AG, Kozyrskyj AL: Outpatient treatment of communityacquired pneumonia: evolving trends and a focus on fluoroquinolones. Can J Clin Pharmacol 2006, 13:e102-e111.
25. Davidson R, Cavalcanti R, Brunton JL, Bast DJ, de Azavedo JC, Kibsey P, Fleming C, Low DE: Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002, 346:747-750.